share_log

Avalo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners III, L.P.(0.0%),VHCP Co-Investment Holdings III, LLC(0.0%), etc.

Avalo Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Venrock Healthcare Capital Partners III, L.P.(0.0%),VHCP Co-Investment Holdings III, LLC(0.0%)等

美股sec公告 ·  02/14 21:18
Moomoo AI 已提取核心訊息
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
包括Venrock Healthcare Capital Partners III、L.P.、VHCP Co-Investment Holdings III, LLC、VHCP Management III, LLC、VHCP Management EG, LLC、Nimish Shah和Bong Koh在內的一系列實體和個人已向美國證券交易委員會提交了經修訂的附表13G/A，表明他們不再以實益方式擁有Avalo Therapeutics, Inc.5％以上的股份。”截至2023年12月31日的普通股。這份日期爲2024年2月14日的文件證實，該集團內每位申報人持有零股份，該集團的所有權爲零，這表明已完全從Avalo Therapeutics撤資。這些實體和個人主要根據特拉華州的法律組建，Shah和Koh是美國公民。該文件確保處置股份的目的不是爲了改變或影響Avalo Therapeutics的控制權。
包括Venrock Healthcare Capital Partners III、L.P.、VHCP Co-Investment Holdings III, LLC、VHCP Management III, LLC、VHCP Management EG, LLC、Nimish Shah和Bong Koh在內的一系列實體和個人已向美國證券交易委員會提交了經修訂的附表13G/A，表明他們不再以實益方式擁有Avalo Therapeutics, Inc.5％以上的股份。”截至2023年12月31日的普通股。這份日期爲2024年2月14日的文件證實，該集團內每位申報人持有零股份，該集團的所有權爲零，這表明已完全從Avalo Therapeutics撤資。這些實體和個人主要根據特拉華州的法律組建，Shah和Koh是美國公民。該文件確保處置股份的目的不是爲了改變或影響Avalo Therapeutics的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息